{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:39:34Z","timestamp":1766504374471,"version":"3.40.5"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Statistics"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The COVID\u201019 pandemic has manifold impacts on clinical trials. In response, drug regulatory agencies and public health bodies have issued guidance on how to assess potential impacts on ongoing clinical trials and stress the importance of a risk\u2010assessment as a pre\u2010requisite for modifications to the clinical trial conduct. This article presents a simulation study to assess the impact on the power of an ongoing clinical trial without the need to unblind trial data and compromise trial integrity. In the context of the CANNA\u2010TICS trial, investigating the effect of nabiximols on reducing the total tic score of the Yale Global Tic Severity Scale (YGTSS\u2010TTS) in patients with chronic tic disorders and Tourette syndrome, the impact of the two COVID\u201019 related intercurrent events handled by a treatment policy strategy is investigated using a multiplicative and additive data generating model. The empirical power is examined for the analysis of the YGTSS\u2010TTS as a continuous and dichotomized endpoint using analysis techniques adjusted and unadjusted for the occurrence of the intercurrent event. In the investigated scenarios, the simulation studies showed that substantial power losses are possible, potentially making sample size increases necessary to retain sufficient power. However, we were also able to identify scenarios with only limited loss of power. By adjusting for the occurrence of the intercurrent event, the power loss could be diminished to different degrees in most scenarios. In summary, the presented risk assessment approach may support decisions on trial modifications like sample size increases, while maintaining trial integrity.<\/jats:p>","DOI":"10.1002\/pst.2100","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T05:25:17Z","timestamp":1613798717000},"page":"675-691","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Potential impact of <scp>COVID<\/scp>\u201019 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the <scp>CANNA\u2010TICS<\/scp> study"],"prefix":"10.1002","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4889-0212","authenticated-orcid":false,"given":"Florian","family":"Lasch","sequence":"first","affiliation":[{"name":"Hannover Medical School  Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-270X","authenticated-orcid":false,"given":"Lorenzo","family":"Guizzaro","sequence":"additional","affiliation":[{"name":"European Medicines Agency  Amsterdam Netherlands"},{"name":"Universit\u00e0 della Campania  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Aguirre D\u00e1vila","sequence":"additional","affiliation":[{"name":"Paul\u2010Ehrlich\u2010Institut  Langen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"M\u00fcller\u2010Vahl","sequence":"additional","affiliation":[{"name":"Hannover Medical School  Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-3219","authenticated-orcid":false,"given":"Armin","family":"Koch","sequence":"additional","affiliation":[{"name":"Hannover Medical School  Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"e_1_2_13_2_1","first-page":"1","volume-title":"Guidance on the Management of Clinical Trials During the Covid\u201019 (Coronavirus) Pandemic","author":"European Commission","year":"2020"},{"volume-title":"Points to Consider on Implications of Coronavirus Disease (COVID\u201019) on Methodological Aspects of Ongoing Clinical Trials","year":"2020","author":"European Medicines Agency","key":"e_1_2_13_3_1"},{"volume-title":"Statistical Considerations for Clinical Trials During the COVID\u201019 Public Health Emergency","year":"2020","author":"U.S. Department of Health and Human Services","key":"e_1_2_13_4_1"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2020.1779122"},{"issue":"0","key":"e_1_2_13_6_1","first-page":"1","article-title":"Clinical trials impacted by the COVID\u201019 pandemic: adaptive designs to the rescue?","volume":"0","author":"Kunz CU","year":"2020","journal-title":"Stat Biopharm Res"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106155"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198907000-00015"},{"issue":"0","key":"e_1_2_13_9_1","first-page":"1","article-title":"Assessing the impact of COVID\u201019 on the clinical trial objective and analysis of oncology clinical trials\u2014application of the Estimand framework","volume":"0","author":"Degtyarev E","year":"2020","journal-title":"Stat Biopharm Res"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2020.1785931"},{"key":"e_1_2_13_11_1","first-page":"1","article-title":"Addendum on Estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9(R1)","author":"International Concil for Harmonisation (ICH)","year":"2019","journal-title":"Fed Regist"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13004"},{"key":"e_1_2_13_13_1","first-page":"1","article-title":"Impact of Italian lockdown on Tourette syndrome at the time of the COVID\u201019 pandemic","volume":"1","author":"Graziola F","year":"2020","journal-title":"Psychiatry Clin Neurosci"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.1995.tb01826.x"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28067"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28069"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2010.0158"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-018-1190-4"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2005.11.551"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1444-0903.2004.00531.x"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-25028"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0417"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2013.08.012"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6122"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2019.1647874"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12982-018-0083-9"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8086"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-31"},{"key":"e_1_2_13_29_1","doi-asserted-by":"crossref","unstructured":"European Medicines Agency.Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders.2018;11:253\u2010259.https:\/\/doi.org\/10.1016\/S0924-977X(01)00085-2.","DOI":"10.1016\/S0924-977X(01)00085-2"},{"volume-title":"Guideline on Clinical Investigation of Medicinal Products in the Treatment of Parkinson's Disease","year":"2012","author":"European Medicines Agency","key":"e_1_2_13_30_1"},{"volume-title":"Guideline on Clinical Investigation of Medicinal Products in the Treatment of Depression","year":"2013","author":"European Medicines Agency","key":"e_1_2_13_31_1"}],"container-title":["Pharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.2100","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pst.2100","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.2100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T03:35:21Z","timestamp":1693539321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pst.2100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/pst.2100"],"URL":"https:\/\/doi.org\/10.1002\/pst.2100","archive":["Portico"],"relation":{},"ISSN":["1539-1604","1539-1612"],"issn-type":[{"type":"print","value":"1539-1604"},{"type":"electronic","value":"1539-1612"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"2020-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}